Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Boehringer Ingelheim Acquires And Divests
by Michael McCoy
January 24, 2011
| A version of this story appeared in
Volume 89, Issue 4
Boehringer Ingelheim will acquire Amgen’s biologic manufacturing facility in Fremont, Calif., and make the plant part of its contract manufacturing network. Amgen obtained the plant, which employs about 260 people, through its 2006 purchase of Abgenix. Boehringer says it will continue to serve Amgen, for which it has been a contract manufacturer for more than 10 years. Separately, Boehringer has agreed to sell its Resomer pharmaceutical polymers business to Evonik Industries. Based on lactic and glycolic acids, Resomer polymers are fully biodegradable in the body, Evonik says.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter